Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 with Atezolizumab, Pemetrexed, and Carboplatin in NSCLC
NCT03498222Phase 1Withdrawn
- Sponsor
- Queen Mary University of London
- Start
- Jun 2018
- Primary completion
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of Pegargiminase in non-small cell lung carcinoma (NSCLC), sponsored by Queen Mary University of London. Planned start Jun 2018; status: withdrawn.
02
Drugs
Pegargiminase
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT03498222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498222.